Vivoryon Therapeutics N.V.

Amsterdam Stock Exchange:VVY.AS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🤖 Artificial Intelligence (AI)

🧬 Biotechnology

💊 Pharmaceuticals

Location

Germany

Market Cap

USD 45.11 M

Share Price

USD 1.73

Avg Daily Volume

53,082

Change (1 day)

-2.36%

Change (1 year)

-21.99%

Change (YTD)

-16.13%

Vivoryon Therapeutics N.V. Free Cash Flow for the year ending December 31, 2024: USD -19.86 M

Vivoryon Therapeutics N.V. Free Cash Flow is USD -19.86 M for the year ending December 31, 2024, a -18.43% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Vivoryon Therapeutics N.V. Free Cash Flow for the year ending December 31, 2023 was USD -24.34 M, a 4.33% change year over year.
Vivoryon Therapeutics N.V. Free Cash Flow for the year ending December 31, 2022 was USD -23.33 M, a 81.63% change year over year.
Vivoryon Therapeutics N.V. Free Cash Flow for the year ending December 31, 2021 was USD -12.85 M, a -28.23% change year over year.
Vivoryon Therapeutics N.V. Free Cash Flow for the year ending December 31, 2020 was USD -17.90 M, a 36.84% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

Amsterdam Stock Exchange: VVY.AS

Vivoryon Therapeutics N.V.

CEO	Dr. Frank T. Weber M.D.
IPO Date	Oct. 27, 2014
Location	Germany
Headquarters	Weinbergweg 22
Employees	14
Sector	🏥 Health Care
Industries Clinical Trials 🤖 Artificial Intelligence (AI) 🧬 Biotechnology 💊 Pharmaceuticals

Description

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.